Wilson disease is a rare genetic disorder that disrupts copper removal, leading to toxic buildup in organs like the liver and brain. It affects about one in 30,000 live births in the United States and causes symptoms such as liver disease and neurological issues.
MNPR-101 is intended to complement existing cancer therapies, not replace them. Its distinct mechanism and non-overlapping toxicity support potential combination treatments, leveraging uPAR’s selective expression in tumors.
MNPR-101 targets the urokinase plasminogen activator receptor (uPAR), which is overexpressed in tumor cells. Preclinical studies show it has anti-tumor activity, and Monopar is advancing it for clinical evaluation.
Monopar Therapeutics' mission is to acquire, develop and commercialize promising oncology product candidates that address the unmet medical needs of cancer patients.
Mr. Anderson has over 30 years of experience in biopharmaceutical financial management, including roles as CFO at BioMarin and Dow Pharmaceutical Sciences, and as a board member at Raptor Pharmaceutical Corp.
Dr. Starr co-founded Raptor Pharmaceuticals in 2006 and oversaw the approval, launch, and commercialization of Procysbi as CEO until 2014. He also co-founded BioMarin Pharmaceutical Inc. in 1997.
